Literature DB >> 18215058

A second-generation total synthesis of (+)-phorboxazole A.

Amos B Smith1, Thomas M Razler, Jeffrey P Ciavarri, Tomoyasu Hirose, Tomoyasu Ishikawa, Regina M Meis.   

Abstract

A highly convergent second-generation synthesis of (+)-phorboxazole A has been achieved. Highlights of the synthetic approach include improved Petasis-Ferrier union/rearrangement conditions on a scale to assemble multigram quantities of the C(11-15) and C(22-26) cis-tetrahydropyrans inscribed with the phorboxazole architecture, a convenient method to prepare E- and Z-vinyl bromides from TMS-protected alkynes utilizing radical isomerization of Z-vinylsilanes, and a convergent late-stage Stille union to couple a fully elaborated C(1-28) macrocyclic iodide with a C(29-46) oxazole stannane side chain to establish the complete phorboxazole skeleton. The synthesis, achieved with a longest linear sequence of 24 steps, proceeded in 4.6% overall yield.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18215058     DOI: 10.1021/jo7018152

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  4 in total

1.  Phorboxazole Synthetic Studies: Design, Synthesis and Biological Evaluation of Phorboxazole A and Hemi-Phorboxazole A Related Analogues.

Authors:  Amos B Smith; Anne-Marie L Hogan; Zhuqing Liu; Thomas M Razler; Regina M Meis; Brandon I Morinaka; Tadeusz F Molinski
Journal:  Tetrahedron       Date:  2011-07-08       Impact factor: 2.457

Review 2.  Synthesis of the phorboxazoles-potent, architecturally novel marine natural products.

Authors:  Zachary Shultz; James W Leahy
Journal:  J Antibiot (Tokyo)       Date:  2016-03-09       Impact factor: 2.649

Review 3.  Thiazole and oxazole alkaloids: isolation and synthesis.

Authors:  Danilo Davyt; Gloria Serra
Journal:  Mar Drugs       Date:  2010-11-05       Impact factor: 5.118

4.  Hemi-phorboxazole a: structure confirmation, analogue design and biological evaluation.

Authors:  Amos B Smith; Zhuqing Liu; Anne-Marie L Hogan; Doralyn S Dalisay; Tadeusz F Molinski
Journal:  Org Lett       Date:  2009-08-20       Impact factor: 6.005

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.